Early trial results leave Imugene patients cancer-free
The first two blood cancer patients taking part in a United States-based trial, who had suffered relapses despite having treatment, have...
top of page
Search
Craig Nolan
- Jul 10
Imugene delivers first Aussie bile tract cancer trial dose
Imugene (ASX: IMU) has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract...
Doug Bright
- Jun 24
Imugene delivers first combo dose in bile tract cancer study
Imugene (ASX: IMU) has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the...
Helen Barling
- Apr 16
Imugene cancer fight bolstered by strategic US partnership
Australian anti-cancer company Imugene (ASX: IMU) has stamped a strategic manufacturing and processing agreement with Kincell Bio, with...
Steve Butler
- Apr 15
Imugene launches pivotal bile tract cancer expansion study
ASX-listed medical technology company Imugene (ASX: IMU) has launched a pivotal expansion study targeting patients with bile tract...
Michael Philipps
- Apr 4
Imugene locks down cancer patent in massive Chinese market
Australian anti-cancer company Imugene (ASX: IMU) has received a patent to protect its unique cancer treatment in China – the largest and...
Michael Philipps
- Mar 11
Imugene to tackle cancer tumours with combo treatment
Imugene (ASX: IMU) has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “onCARlytics” treatment for...
Michael Philipps
- Feb 15
Imugene advances search-and-destroy cancer mission
An Australian-based medical mission to flesh out and kill cancerous cells in humans has received a boost after ASX-listed medtech Imugene...
Doug Bright
- Jan 19
Imugene extends anti-cancer trial following recent successes
Following recent successes, Imugene has advanced its Phase 1 clinical study with the first Cohort 5 patients now receiving doses of the...
Doug Bright
- Jan 17
Imugene to expand cancer treatment trial following early success
Clinical stage immune-oncology company Imugene has reported some eye-catching results in an update of its Phase 1 trial to assess the...
Doug Bright
- Dec 12, 2023
Imugene out to supercharge cancer patients in new alliance
Imugene has joined with United States-based NeoImmuneTech (NIT) for a two-year collaboration aimed at combining their respective...
Michael Philipps
- Dec 6, 2023
Imugene on brink of European patent for cancer drug
Imugene expects to secure a crucial patent for its “PD1-Vaxx” lung cancer vaccine from the European Patent Office this month, with a...
Doug Bright
- Nov 28, 2023
Imugene cancer virus earns crucial FDA fast-track status
The US Food and Drug Administration has stamped Imugene’s “Vaxinia” drug trials aimed at treating bile duct cancer with “fast-track”...
Michael Philipps
- Nov 13, 2023
Cancer-fighting mission shoots Imugene up ASX boards
Cancer. In modern days of fast vehicles and seemingly even faster living, there are few people or families who have not been touched by...
Doug Bright
- Nov 10, 2023
Holy grail cancer treatment one step closer for Imugene
Imugene has continued to set the ASX boards alight after revealing it had delivered the first dose of its azer-cel therapy to a patient...
Helen Barling
- Nov 6, 2023
Hope grows with positive signals in Imugene cancer trial
Australian immune-oncology company Imugene has recorded positive early signals from the first phase of its metastatic advanced solid...
Doug Bright
- Nov 2, 2023
Imugene enters final stages of cancer tumour trials
Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for...
Helen Barling
- Oct 26, 2023
Imugene kicks off world-first cancer drug trial
In a world first, ASX-listed medtech Imugene has dosed the first cancer patient with its novel onCARlytics CD19 virus technology which it...
Helen Barling
- Oct 24, 2023
Imugene trials take centre stage at global cancer congress
Imugene is poised to secure further development opportunities for its “super-charged” cell immunotherapy programs after putting them on...
Doug Bright
- Sep 28, 2023
FDA clears licence pathway for Imugene cancer trials
The United States Food and Drug Administration has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer...
bottom of page